Monoclonal Antibodies and Antibody-Drug Conjugates: Expanding the Therapeutic Arsenal in Multiple Myeloma.
Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) have significantly expanded the therapeutic landscape of multiple myeloma (MM), contributing to deeper and more durable responses and meaningful survival benefits across the continuum of the disease. CD38-targeting mAbs are now integral to frontline regim...